Paula Sayegh, PharmD, BCPS, BCOP

Pharmacist with a love for oncology pharmacotherapy, caring for every patient and learning from every patient

[Aakash Desai, MD, MPH, FASCO @ADesaiMD]

LAURA Ph 3: Osimertinib vs Placebo #ASCO24 @ASCO

➡️ mPFS: 39.1 vs 5.6 mo (HR 0.16) ‼️
➡️ 24-mo PFS: 65% vs 13% 📈
➡️ 81% received osi at progression 💊, Good!
➡️AE discontinuation**: 13% vs 5% ⚠️

Can't wait for @RamalingamMD's presentation today! �� #ASCO24 @OncoAlert Data courtesy: @FordePatrick’s tweet! @OncoAlert

[NEJM @NEJM]

Among patients with cancers bearing the KRAS G12C mutation who received divarasib at a 400-mg dose, 56% with lung cancer, 36% with colorectal cancer, and 36% with other tumor types had a confirmed response.

🔗 Read the full study results: https://t.co/qhLT0MvQx8

#oncology

[Paolo Tarantino @PTarantinoMD]

Both T-DXd and SG are approved for patients with HER2-low TNBC. But which one has the strongest data in support? Which one should be utilized first? Find the answer in our latest letter to the editor, now published on @Annals_Oncology. @curijoey @stolaney1 https://t.co/KqE0aC8FcL

[H. Jack West, MD, FASCO @JackWestMD]

Let's be clear: OS results are neg for OS benefit in PD-L1+ NSCLC. If we're going to rely on smaller subgroups to highlight the HR of 0.43 for those w/high PD-L1, we should also note HR for OS was 0.95 (i.e., NO trend of OS benefit) for those w/PD-L1 1-49%.

As w/KN-042.

With favorable results driven entirely by a 30% subgroup, it's understandable that Roche would want to also promote benefit in broader population. But we shouldn't perpetuate misinformation that there's a benefit for broad group of PD-L1+, even if the effort is to market it this way.

[Targeted Oncology @TargetedOnc]

Dato-DXd led to a statistically significant improvement of PFS vs docetaxel for patients with locally advanced or metastatic #NSCLC who received at least 1 prior therapy in the TROPION-Lung01 phase 3 trial. #lcsm

https://t.co/pdGmGDOklq

[ASCO @ASCO]

"Today’s #drugshortages are the worst I have seen in my 30-year career… PAHPA reauthorization is an opportunity to advance solutions to improve the supply chain—especially during public health crises�� - ASCO CMO @jrgralow. Read more: https://t.co/A0kn0eozWL #ASCOAdvocacy

[Michael Duruisseaux @MDuruisseaux]

CheckMate 722: an highly anticipated randomized trial that compared chemo nivo to chemo in EGFR + NSCLC resistant to TKI.
No efficacy signal despite underpowered, no convincing PD L1 selection data.
The end of chemo IO in this setting?
@OncoAlert

[NEJM @NEJM]

Original Article: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC (ADAURA) https://t.co/DhBGR7cDIr

#ASCO23

[ASCO @ASCO]

Update on #drugshortages: @US_FDA just announced it will temporarily import cisplatin. This is an impt first step toward alleviating the critical #drugshortage and ensuring clinicians can deliver the best cancer care possible. Check https://t.co/mPWChjj3yy for the latest info.

[Mark Lewis, MD, FASCO @marklewismd]

Some people say “nobody wants chemo” as if they’ve found the Achilles heel of medical oncology.

Right. Nobody *wants* chemo.

But the truth is that many patients *need* chemo which is in very short supply.

Kudos to @doctormb1 for calling attention to drug shortages at #asco23👇🏻

[NEJM @NEJM]

Presented at #ASCO23: In the KEYNOTE-671 trial, pts with resectable lung cancer were assigned to neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo. Two-year event-free survival was 62.4% with pembrolizumab & 40.6% with placebo.

[Paula Sayegh, PharmD, BCPS, BCOP @PaulaSayegh]

@nickeIodeonnfts 😻 @acefirefist12 @maria_stifler @Lorranakaolainy @moni_benito @Guhpereira28 @Toniruizsanchez @NFTWoIf @meryshella @PierreZoots @Adrienn0HBAR @BDeztiny @pizzaBotticelli @Just1nThyme_NFT

[Paula Sayegh, PharmD, BCPS, BCOP @PaulaSayegh]

@nickeIodeonnfts Claimed ✅ @NukiNFT @NoraHigbee2 @amivanalexander @NFTQuiss @Avery67522036 @yunivoxel @Tindi_official @janluisw @Zurex__ @MitchLandewee @Olamidega @GrumpyaliensNFT @Kmellway01

[Paula Sayegh, PharmD, BCPS, BCOP @PaulaSayegh]

@nickeIodeonnfts 🌈🌈 @0xBaboo37 @YoodlesART @chiehyu1993618 @KiefinIt100 @old_lady1908 @flixster_r @PaffortX @Laatokoshero_ @BKK_BROS @sebvae1 @CamsMey_ @rramen999 @kaljobaimee_or

[Paula Sayegh, PharmD, BCPS, BCOP @PaulaSayegh]

@nickeIodeonnfts No 🧢 @evocoin_ @le28531918 @MainlyArpit @VillafanaIker_ @astralsonx @SloppyToppy1210 @nifranif_ @bramalleman @ethanical_ @GamblingOg @linedsheets @gotDurrrred111 @d_schaefer_nft